Silence Therapeutics PLC Minority Stake in Arrowhead Pharmaceuticals (1602U)
January 13 2017 - 8:03AM
UK Regulatory
TIDMSLN
RNS Number : 1602U
Silence Therapeutics PLC
13 January 2017
Minority stake in Arrowhead Pharmaceuticals
13(th) January 2017
London, 13(th) January 2017 - Silence Therapeutics plc, AIM:SLN
("Silence" or the "Company") a leader in the discovery, delivery
and development of novel RNA therapeutics for the treatment of
serious diseases with unmet medical need, provides an update to its
announcement on 9(th) January 2017 regarding the acquisition of a
minority stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
("Arrowhead").
Silence has today filed a Schedule 13D with the US Securities
and Exchange Commission ("Schedule 13D"). Following additional
purchases made by the Company since the 9(th) January, the Schedule
13D sets out that Silence, as at 13(th) January 2017, directly owns
6,831,359 common shares of Arrowhead, representing 9.21% of the
outstanding share capital of Arrowhead. In aggregate, Silence has
paid a total consideration of $11.3 million to acquire the
6,831,359 common shares.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE MARKET ABUSE REGULATION (EU No. 596/2014). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE
THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Canaccord Genuity Limited (Nominated Tel: +44 (0)20
Adviser and Joint Broker) 7523 8350
Rupert Winckler/Henry Fitzgerald-O'Connor/Emma
Gabriel
Peel Hunt LLP (Joint Broker) Tel: +44 (0)20
James Steel/Oliver Jackson 7418 8900
Media Enquiries: Tel: +44 (0) 20
FTI Consulting 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Our technology harnesses the body's natural mechanisms to create
therapeutic effects within its cells. This technology can
selectively silence or replace any gene in the genome, modulating
gene expression up as well as down in a variety of organs and cell
types, in vivo. We have developed proprietary modifications to
improve the robustness of RNA sequences, as well as advanced
chemistries to enhance the effective delivery of therapeutic RNA
molecules to target cells.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFUFDDFWSEDF
(END) Dow Jones Newswires
January 13, 2017 09:03 ET (14:03 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024